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The purpose of this dissertation is to assess the potential neuroprotective effect of
an alpha7 nAChR agonist, PNU-282987, and modulator, PNU-120596, in an in vitro
model of excitotoxicity and an in vivo model of acute glaucoma.

In in vitro studies,

retinas obtained from Long Evans rats were cultured using various concentrations of the
PNU compounds to analyze neuroprotection against glutamate-induced excitotoxicity.
After 3 days in culture, RGCs were identified using an antibody against Thy 1.1,
visualized using a fluorescent dye and quantified.

In culture, glutamate significantly

decreased the number of RGCs. However, if either PNU compound was introduced
before the glutamate insult, higher survival of cells was observed.

In in vivo studies,

PNU compounds were injected intravitreally to determine their potential neuroprotective
effect in a rat glaucoma model. Following treatments with PNU compounds, surgery was
performed to induce glaucoma-conditions by injecting 0.05ml of 2mM NaCl into the
episcleral veins of right eyes in each rat. The left eye in each rat was left untreated. After
one month, rats were euthanized, retinas were removed, flat mounted, fixed and nuclei
were stained with cresyl violet or immunostained with an antibody against Thy 1.1.
Stained nuclei in the RGC layer in glaucoma-induced retinas were counted and compared
to cell counts from untreated retinas. The surgery to induce glaucoma-like conditions

caused a significant loss of cells in the RGC layer within 1 month after surgery.
However, this effect was eliminated if either PNU compound was injected into the right
eye an hour before surgery. The results from this thesis support the hypothesis that the
alpha7 agonist, PNU-282987 and modulator, PNU-120596, have a neuroprotective effect
in the rat retina. PNU-282987 and PNU-120596 may be viable candidates for future
therapeutic pretreatment of glaucoma.
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SPECIFIC AIMS

Glaucoma is a degenerative retinal disease characterized by loss of vision
due to the progressive loss of retinal ganglion cells (RGCs). In several in vitro
models of glaucoma, death of RGCs is induced by excessive neurotransmitter that
triggers excitotoxicity and apoptosis. Recently, a great deal of research has explored
agents and mechanisms that provide neuroprotection against excitotoxicity.
Neuroprotection is a process where neurons are protected from injury or
degeneration.

In previous studies from this lab, both acetylcholine (ACh) and

nicotine have been found to be neuroprotective in the retina and act to prevent
glutamate-induced excitotoxicity in an isolated cultured pig RGC preparation
(Wehrwein et al., 2004). Other pharmacological studies using pig cultured RGCs
have demonstrated that activation of specific a7 nicotinic acetylcholine receptors
(nAChRs) are linked to this neuroprotection (Wehrwein et al., 2004; Thompson et al.,
2006).

However, it is unclear if these al nAChRs have any significant

neuroprotective role against RGC loss associated with glaucoma.

To address this

issue, the al nicotinic agonist, PNU-282987, and the al nicotinic allosteric
modulator, PNU-120596, will be analyzed in an in vitro model of excitotoxicity and

1

an in vivo rat model of glaucoma to test the hypothesis that introduction of al
nicotinic agonists or modulators can reduce the loss of cells in the RGC layer that is
normally associated with glaucoma.

To test this hypothesis, 2 specific aims were

designed.

1) To determine if the a7 nicotinic agonist, PNU-282987, has a neuroprotective
effect in the rat retina

Recent pharmacological advances have developed PNU-282987, an agonist
specific for the al nicotinic receptor. In this study, I will introduce this specific al
nicotinic agonist to cultured rat cells and to an in vivo model of glaucoma in the rat
to determine if PNU-282987 reduces the cell death normally associated with
excitotoxicity (in vitro model) and to determine if PNU-282987 reduces the loss of
cells in the RGC layer normally associated with the in vivo rat glaucoma model. In
the in vitro model, rat retina will be dissociated and cultured in the presence or
absence of PNU-282987 compound before inducing excitotoxicity with excessive
glutamate. After 3 days, rat RGCs will be identified, counted and compared to
untreated conditions using a fluorescently labeled antibody against Thy 1.1 (a
glycoprotein on RGCs in the retina). In the in vivo model, PNU-282987 will be
2

injected into the vitreous of a rat eye prior to inducing glaucoma-like conditions.
Glaucoma-like conditions will be induced in the right eye of each rat used in the
study by injecting hypertonic saline into the episcleral vein according to the method
described by Morrison et al. (1997). This technique creates scar tissue and increases
intraocular pressure, which is the primary risk factor associated with glaucoma.
Using this method, significant loss of cells in RGC layer occurs within one month
(Morrison et al., 1997). After a month, the retina of the control left eye and the
glaucoma-induced right eye will be removed, cells in the retina will be stained with
cresyl violet or an antibody against Thy 1.1 and the number of cells in the RGC
layer will be counted and compared.

2) To determine

if

the

al

modulator,

PNU-120596,

enhances

the

neuroprotective effect of PNU-282987 on rat RGCs.

The compound PNU-120596 has been shown to be an allosteric modulator
that binds to the al nicotinic receptor (Hurst et al., 2005). In previous in vitro
studies using pig isolated RGCs, this modulator, in conjunction with PNU-282987,
has been shown to enhance the neuroprotective effect of PNU-282987 alone (Linn C.
et al., 2011). In this study, in vitro studies will be duplicated in the rat using a
3

combination of the al agonist and modulator to determine if the modulator enhances
the neuroprotective effect described in pig studies. The combination of the al PNU
agonist and modulator will also be used in the in vivo rat glaucoma model to
determine if the modulator enhances the effect of the agonist and provides
neuroprotection against loss of cells in the RGC layer normally associated with
glaucoma. The results from these studies provides evidence that ACh-induced
neuroprotection against glutamate-induced excitotoxicity in cultured rat RGCs is
mediated through al nicotinic receptors and that loss of cells in the RGC layer due
to glaucoma-like conditions can be prevented with a7 PNU compounds. These are
the first studies that analyze the effects of these al agents in an in vivo model of
glaucoma.

4

INTRODUCTION

The Retina

The sense of vision is one of the fundamental senses we use to perceive the
world around us. The neuronal part of the eye, the retina, converts photons into
electrochemical signals. For the light to reach the retina, it must pass through
several parts of the eye before being detected in the retina. Figure 1 illustrates the
anatomy of the vertebrate eye. Light must pass through the anterior parts of the eye
before it reaches the photoreceptors in the retina where phototransduction occurs.
Photons must first pass through the cornea, which is modified sclera. The cornea
works to protect the anterior parts of the eye and to refract light into the eye. The
iris, which is characterized as the colored pigmented part of the eye, is a group of
muscles that define the size of the pupil to adjust the amount light that enters the eye.
After light passes through the pupil and lens, majority of the signal it is focused onto
the fovea.

The fovea contains the highest concentration of cone receptors and

produces the highest visual acuity. The lens is controlled by a group of muscles
called the ciliary body. When the ciliary body contracts, the lens becomes convex;
when it relaxes the lens becomes more flat. The changing shape of the lens allows
us to focus on things at different distances, a process called accommodation. The
5

ciliary body also plays an important role in the eye by producing aqueous humor.
Aqueous humor is a liquid that provides oxygen and nutrients to the anterior
chamber of the eye. The pressure produced by aqueous humor plays an important
role in our visual health.

choroid
sclera
\ . , _ /
retina
cornea
fovea
pupil

lens
optic
iv.jn/e

ins
ciliary
body
Figure 1: Anatomy of the eye

Light must pass through the cornea and lens before it is focused on the fovea of the
retina. (Modified from Kolb, 2003)

The retina is part of the central nervous system and is located at the back of
the eyeball. Its main function is to receive light information and to transduce it into
electrochemical impulses and send that information into the brain. Light that enters
the eye is converted into electrical signals in the photoreceptors. In the mammalian
6

retina, the photoreceptors can be divided into 2 different types, rods and cones.
Rods have broad rod-shaped cell bodies and are used for dark and dim vision. The
other type of photoreceptor is called the cone, which has a smaller conical shaped
head and is used for color vision. In the human, the cones can be separated into 3
different types depending on the color of light that is perceived, blue, green, and red.
Rods are located throughout the retina with more rods around the periphery, whereas
cones are centralized and concentrated on the fovea of the eye. Rods are more
numerous than cones in the human retina, containing approximately 120 million rod
and 6 million cones.
Compared to the human trichromatic vision, rats have 2 types of cones, blue
and green, but lack the red cones (Jacobs et al, 2001). This means rats are virtually
blind to the color red and relatively longer wavelengths. However, rats can see into
the ultraviolet range, which humans cannot see, as a result of blue cones that
perceive shorter wavelengths (Jacobs et al., 1991).
Rats in general are considered to have relatively poor vision. Visual acuity is
measured by the ability to distinguish between distinct small details of an object.
The unit for this measurement is called cycles per degree (CPD), and in humans this
number is around 30, compared in 1 CPD in Long-Evans rats (Prusky et al., 2000).
This translates to rat vision being 20/600 compared to a normal human's 20/20
7

vision. However, even though their visual acuity is not as good as human eyes, the
rat model remains an excellent model to analyze retinal diseases that affect RGCs, as
their retinas have similar tissue structure and neurotransmitters as human retina.
0
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Figure 2: Schematic of mammalian retina
This figure illustrates the connection and different layers formed by neurons in the
vertebrate retina. Each cell type works to pass the light signal from the
photoreceptors through the layers of the retina to the brain. Some are directly
connected vertically while others work to modulate the signal as it travels through
the retina. (Modified from Kolb, 2003)

Within the retina, the photoreceptors are located in the deep layer of the
retina, situated against the pigment epithelium. All vertebrate retinas can be divided
into 3 nerve cell layers and 2 synaptic layers (fig. 2) The outer most cell layer,
8

called the outer nuclear layer (ONL), is where the photoreceptors are located. This
layer transduces the light signal into electrochemical signals and transmits it through
the retina.

This process of the photoreceptors converting light signal into

electrochemical signals is called phototransduction. From the outer most layers
where the photoreceptors are located, the rest of the layers through the retina are
defined as the outer plexiform layer (OPL), inner nuclear layer (INL), inner
plexiform layer (IPL) and the retinal ganglion cell (RGC) layer. The RGC layer
contains cell bodies of the RGCs and is the last layer to receive before sending
visual information to the brain. The axons from the RGCs form the optic nerve and
send the signals to the brain.
The plexiform layers are where synaptic connections occur. The first of
these plexiform layers is the OPL where the synapse of photoreceptors and bipolar
and horizontal cells occur. The bipolar cells are connected between the vertical
processes, while horizontal cells are horizontally located within the OPL layer (Fig
2). The bipolar cells are interneurons that connect the photoreceptors to RGCs.
Horizontal cells synapse with photoreceptors within the OPL to help regulate the
signal and are responsible for surround inhibition in the outer retina.
Within the PNL, cell bodies of horizontal, bipolar, and amacrine cells work
together to process the visual signal. The IPL is where these inner neurons synapse
9

onto ganglion cells, the next order of neuronal cells. The last layer or organization
in the retina is called the RGC layer and contains the ganglion cells and a small
percentage of displaced amacrine cells (Perry et al., 1980; Keyser et al., 2000).
Many retinal diseases, including glaucoma and ischemia, affect the RGC
layer and all retinal diseases that damage these cells result in loss of vision and can
lead to blindness (Selles-Navarro, 1996). Since the RGC layer is the last layer to
receive information before the information is sent to the brain, protecting the RGCs
from apoptosis due to disease is a relevant area of research directed towards
preventing blindness. This is also the focus of my research.
There are 2 major functional types of RGCs, characterized by their cell body
size and their projections to the lateral geniculate nucleus (LGN), the primary
processing center in the brain for visual information.

The small RGCs have

relatively small cell bodies and relatively short dendrites. These types of RGCs
projects into the parvocellular layer of the LGN and responds mainly to color
changes and not to contrast, which suggests their role in color vision. The larger
type of RGC is called parasol cells and projects their axons mainly into the
magnocellular layer of the LGN. Parasol cells are used for contrast detection and
are not very sensitive to color changes.
From the LGN, the visual information is sent to the visual cortex. Each
10

hemisphere of the brain contains a region designated as the visual cortex, which is
divided into the primary visual cortex (VI), and extrastriate visual cortical areas,
V2-V5. From the VI, the visual information is split into 2 pathways, the dorsal and
the ventral stream. The dorsal stream, which is also called the "where pathway",
goes to the V2 and V5 pathway and is associated with visual location and motion.
The ventral stream, which is also called the "what pathway", is associated with
object recognition.
The eye is considered to be an extension of the central nervous system
(CNS) as the tissue is derived from central neural tissue during development. Many
CNS treatments used in the brain for Alzheimer's, Parkinson's and other
neurodegenerative diseases are applicable to the retina because of this fact. In my
experiments I will be focusing on neuroprotection in the RGC layer and use this
layer of the retina to quantify cell survival or cell loss and will propose treatments
that specifically affect cell survival in the RGC layer.

Phototransduction

The photoreceptors are responsible for phototransduction, which is the
process where photons are converted into electrical signals. When stimulated with a
photon of light, vertebrate photoreceptors respond with a hyperpolarization. The
11

key molecule responsible for phototransduction is called rhodopsin, which consists
of opsin, a G protein-coupled receptor and an aldehyde of vitamin A, called 11-cis
retinal (Hubbard and Wald, 1952).
When photons of light hit this pigment molecule, the retinal is converted
from ll-cis to a\\-trans retinal (Mcbee et al., 2001). This conformational change
starts a signaling cascade known as phototransduction. In this process, opsin that is
bound to the retinal can no longer fit because of the conformational change and
rhodopsin changes to metarhodopsin II. This in turn activates transducin, which is
responsible for activating phosphodiesterase. Phosphodiesterase plays a role in
controlling cGMP levels and when activated, hydrolyzes cGMP into GMP. This in
turn decreases the cGMP concentration which in turn closes cGMP-gated channels.
The closure in the non-specific cGMP-gated channels causes a hyperpolarization of
the cell in the vertebrate retina, decreasing the influx of sodium and calcium through
the channels (Baylor, 1996). The resulting hyperpolarization of the photoreceptors
decreases the amount of the photoreceptor neurotransmitter, glutamate, to be
released.
The photoreceptors are synaptically connected to bipolar cells, which make
synaptic connections onto RGCs. In between these direct vertical connections are
horizontal and amacrine cells that are involved in lateral inhibition. The bipolar
12

cells that bind to glutamate can be depolarized or hyperpolarized. The bipolar cells
that depolarize to glutamate released from photoreceptors are considered off-bipolar
cells whereas the ones that hyperpolarize in the presence of glutamate are called on
bipolar cells. The 2 different types of bipolar cells contain different types of
glutamate receptors. The off-bipolar cells contain AMPA/kainate receptors which
are ionotropic glutamate receptors and the on-bipolar cells have metabotropic
glutamate receptors that are linked to a type of G-protein coupled receptor (Dowling
1969).
At least 25 types of amacrine cells have been identified in mammals based
on the variety of neurotransmitters located in the cells (Vaney et al., 1989; Mariani,
1990; Kolb et al., 1992). Some amacrine cells release neurotransmitters like GABA,
dopamine and serotonin while others release peptides such as somatostatin (Vaney,
1986; Ishimoto et al., 1986).

In this study, I am particularly interested in the

starburst amacrine cells that release ACh, as we have previously demonstrated that
ACh can induce neuroprotection in cultured pig studies (Wehrwein et al., 2005).
The photoreceptors, on- and off-bipolar cells, and lateral inhibition from the
horizontal and amacrine cells, produce what it called a receptive field at the RGC
level. The receptive field of the visual system is shaped in an annular manner where
stimulation of the middle inner ring of the receptive field produces a response
13

opposite to responses recorded when the outer ring of the receptive field is
stimulated. There are 2 types of receptive fields found in RGCs. The "on" center
receptive field responds best when light is shined on the center of the ring but does
not react to light that is shined onto the outer ring. The "off center receptive field
on the other hand responds maximally to light that is shined onto the outer ring (Fig
3). This receptive field structure produces size selectivity as well as a spatial
selectivity. Each RGC is tuned to respond to a certain-sized light stimulus and has a
preference to the direction of the light stimulus. This preference in direction of light
is imperative to movement detection (Tadin et al., 2003). RGCs receive a wide
variety of visual stimuli that is filtered and processed for contrast detection and
movement detection before it is sent to the brain and perceived in the visual cortex.

14
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Figure 3: Receptive fields of RGCs
There are 2 main classes of receptive fields. The on-center receptive fields react
best to light that is shone onto the center part of the ring, the off-center receptive
field responds best to annular illumination that shines on the outer ring, but does not
respond to light shone in the middle.

Neurotransmitters and receptors

The key-to-lock comparison is usually used to describe the neurotransmitter
and receptor relationship. For example, a key is needed to unlock a door, and
though there may be one key that unlocks a certain door, there can be various other
keys that can open the same door as well. Many neurotransmitters in the retina work
like a master key that can unlock many doors to transmit visual information.
The vertebrate retina uses several different neurotransmitters including,
gamma aminobutyric acid (GABA), glycine, glutamate and ACh, to name a few
15

(Miller et al., 1981, Glickman et al., 1982). A substance that binds to a receptor and
causes a response is called an agonist. There are many agonists in the mammalian
system that are produced endogenously and others agonist drugs that can be applied
exogenously to mimic the endogenous agents.
Within a receptor family, there are metabotropic and ionotropic receptors.
Ionotropic receptors are receptors that are linked to channels that pass through ions
such as Na+ or Ca2+ when activated.

These produce a depolarization or

hyperpolarization in the cell, depending on what ion is passing through.
Metabotropic receptors, when activated, trigger a G-protein and a second messenger
system to start a cascade of events (Nicholls et al., 2001).
metabotropic receptors results in phosphorylation of proteins.

Activation of
In general, the

ionotropic receptors are very quick activating and the open or closure of the
channels do not last long and only affect a very small region near the receptor.
Activation of metabotropic receptors initiate a cascade of biochemical events that
are triggered by activation of a G protein complex and ultimately cause activation of
a protein kinase that phosphorylates proteins to create a physiological response.
Activation of metabotropic receptors leads to longer duration responses, and can
have a wide variety of effects within the cell.
Glutamate receptors (GluR) are a class of receptors that are found throughout
16

the mammalian body because of its wide use in the nervous system. Glutamate
receptors are also important receptors within the retina, and glutamate functions as
the main transmitter within the retina. GluRs can be found on a number of cells in
the retina, including photoreceptors, bipolar cells and RGCs. The glutamate receptor
family can be characterized into ionotropic and metabotropic subtypes. Ionotropic
GluRs can be further divided into 3 major subtypes. These subtypes, N-methyl-Daspartic acid (NMDA) receptor, kainic acid (KA) receptor and a-amino-3-hydroxyl5-methyl-4-isoxazole-propionate (AMPA) receptors, are named for the agonist that
has the highest affinity for these subtypes (Seeburg, 1993). These subtypes of
ionotropic GluRs are found in the retina. In the mammalian retina, both ionotropic
and metabotropic types of GluRs can be found (Gilbertson et al., 1991; Duvoisin et
al., 1995).
Another important receptor on the retinal cells is the AChR. Both ionotropic
and metabotropic AChRs can be found in the retina. All of the AChRs in the retina
are located on the amacrine cells and RGCs. The ionotropic AChRs are usually
referred to as the nicotinic AChRs (nAChR), as the receptor has a high affinity for
nicotine. There are also other ionotropic types that are not affected by nicotine. The
metabotropic AChR are referred to as the muscarinic AChRs (mAChR) because of
the high affinity to muscarine.
17

Vertebrate RGCs contain both the nicotinic (ionotropic) and muscarinic
(metabotropic) classes of ACh receptors (Keyser el at. 1993). ACh is released onto
RGCs from a population of cells in the retina called starburst amacrine cells (Tauchi,
1984). This population of amacrine cells that release ACh look like exploding
fireworks (Famiglietti 1983, Masland 1998) and are located in the inner nuclear layer
of the retina and as well as in the RGC layer. They receive strong inputs from the
bipolar cells and synapse directly onto RGCs. It is unknown if ACh release from
amacrine cells is compromised under glaucoma conditions.
Nicotinic AChRs have been particularly well studied because of their function
in many tissues throughout the body. Functional nAChRs are composed of 5 nAChR
subunits. Twelve subunits have been cloned in mammals. Nine different a (a2- alO)
and three different P (p2- P4) subunits have been cloned. (Sargent, 1993; McGehee et
al., 1995; Elliott et al., 1996). These subunits are further divided into different
families and further into smaller categories depending on their protein structure.
Functional AChRs can contain different combinations of nAChR subunits or can be
composed of five al subunits (Hellstrom-Lindahl et al., 1999). Nicotinic receptors
have been a target for potential neuroprotective mechanisms in schizophrenia,
Alzheimer's, and even as an analgesic agent (Arneric et al., 2007). Earlier studies

18

done in our lab have implicated nAChRs on RGCs as a potential target for
neuroprotection in the retina and RGCs (Wehrwein et al., 2004).

Glaucoma and excitotoxicity

Glaucoma is a progressive neurodegenerative disease that results in vision
loss due to loss of RGCs. Although there are many types of glaucoma, the one
common characteristic of all types is optic neuropathy. When axons in the optic
nerve are lost or damaged, visual information is not conveyed to the brain and visual
perception is lost. Glaucoma is one of the leading causes of blindness worldwide
and affects over 2.2 million Americans a year. With the population rapidly aging,
the number is suspected to increase by 70% in the relatively near future to over 3
million new cases a year (Congdon et al., 2004). Blindness caused by glaucoma is
irreversible. The primary risk factor associated with glaucoma is the increase in
intraocular pressure (IOP).
There are 2 types of glaucoma that do not result from genetic abnormalities
or drug side effects.

These two types of glaucoma are known as open-angle

glaucoma and closed-angle glaucoma. To understand these 2 types of glaucoma, it's
important to understand the drainage system in the front part of the eye. The
anterior part of the eye contains a chamber in front of the lens that is filled with a
19

clear liquid called the aqueous humor. This fluid, secreted by the ciliary body, is
responsible for providing oxygen and nutrients to the front part of the eye. This
aqueous humor is continuously produced and filtered out via the trabecular
meshwork. However, when the trabecular meshwork's filtering process is slowed
for any reason, the aqueous humor builds up in the front of the eye and causes an
increase of IOP. The most common type of glaucoma, open-angle glaucoma, occurs
from the gradual increase in the IOP.

This may be associated with a gradual

blockage of the meshwork, or when the aqueous humor inflow does not equal the
outflow. People with a family history of open-angle glaucoma are at a higher risk
(Tielsch et al., 2004). African Americans and people from African decent also have
a higher occurrence of this type of glaucoma which provides evidence for a
hereditary aspect in glaucoma (The Eye Diseases Prevalence Research Group, 2004).
The other type of glaucoma is called closed-angle glaucoma, which is an acute form
of glaucoma resulting from blockage of the drainage system of the eye. This is
usually associated with pain in the eye and, if not treated immediately, can result in
blindness.
Currently the two main treatments for glaucoma are drugs or surgery. Either
applied topically or orally, drugs can be administered to decrease the production of
aqueous humor or can increase the drainage of fluid to decrease the IOP (Damji et
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al., 2003). Beta-blockers are a popular class of drugs that are usually applied as eye
drops and are used to decrease aqueous humor production (Brooks and Gillies,
1992). Another class of drugs, called prostaglandins, act by increasing aqueous
outflow from the eye (Toris et al., 1992). Both popular classes of drugs, sometimes
used in combination with one another, result in decreasing IOP. In other instances, a
surgical tool is used to cut small holes in the eye to drain the aqueous humor, or a
laser can be used to poke holes through the trabecular meshwork (Cairns, 1968;
Savage et al., 1988). All of the current treatments of glaucoma are designed to
decrease the IOP. However, in most cases, decreasing the IOP is insufficient to stop
the disease and the progression of blindness does not cease. In some cases, people
with normal IOP still develop vision loss, which indicates that something other than
increased IOP may be causing the vision loss. Another condition, known as
excitotoxicity, is also associated with glaucoma and may be the reason for the
progression of the disease, even if IOP pressure is under control (Quigley, 1999).

Excitotoxicity

In recent years, glutamate is thought to be involved in excitotoxic conditions
involved with glaucoma (Vickers et al. 1995).

Glutamate is the main

neurotransmitter released from photoreceptors and bipolar cells. Previous studies
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done in this lab have determined that high concentrations of glutamate (500uM for 3
days) in cultured pig RGCs can result in upwards of 40% RGC loss (Wehrwein,
2004). Using specific antagonists, it was determined that the excitotoxic effect on
these pig RGCs is mediated by both NMDA and non-NMDA ionotropic glutamate
receptors.
Excitotoxicity is the process of apoptosis of neuronal cells caused by over
stimulation of receptors. Excessive stimulation of these excitatory amino acids
receptors is associated with many neuronal diseases including Parkinson's disease
and Alzheimer's (Choi, 1988). This same concept can be applied in the retina as
well, and is thought to be involved in glaucoma and ischemia. One of the theories
involving excitotoxicity in glaucoma is that as pressure builds up in the anterior part
of the eye, it can cause the RGCs in the retina to die. Cell death causes glutamate to
be released in the retina and vitreous humor. With excess amounts of glutamate
released from dying RGCs, there is overstimulation of glutamate receptors on the
RGCs. This causes a positive feedback effect that causes non-specific cations
channels to open and leads to apoptosis of the RGC by activating kinases and cell
death pathways (Olney, 1977). In my proposed study, high concentrations of
glutamate will be used to induce excitotoxic effects in the rat retinal cells in an in
vitro model of excitotoxicity. In addition, to supplement the in vitro model, in this
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study, hypertonic solution will be injected into the episcleral veins of rat eyes in an
in vivo model to induce glaucoma. This in vivo glaucoma model will be used to
determine if neuroprotection of cells in the RGC layer can occur under glaucomalike conditions.

Apoptosis

One of the mechanisms involved in excitotoxic death of RGCs is apoptosis.
Apoptosis is defined as programmed cell death, and is mediated by a family of
proteins that send the signal to the cell to initiate cell suicide.

One of the

mechanisms for apoptosis is through molecules released from mitochondria that
activate cleaving proteins called caspases (Fesik, 2001). When apoptotic signals,
such as high intracellular calcium, are evident, cytochrome c is released from the
mitochondria to activate the caspases (Martinez-Cballero, 2005). These apoptotic
proteins are associated with creating pores on the outer membrane of the
mitochondria or increasing the permeability of the membrane. The outer membrane
permeability is also regulated by anti-apoptotic genes such as the bcl-2 family of
proteins (Dejean et al., 2005). In previous studies from this lab, it has been shown
that glutamate excitotoxicity in cultured pig RGCs involves phosphorylation of the
p38 MAPK signaling pathway during apoptosis, while ACh triggers PI3K and
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phosphorylation of Akt, which is involved in neuroprotection (Asomugha et al.,
2010).

Neuroprotection

Neuroprotection is defined as prevention of excitotoxicity. Studies done in
the brain have shown that in Alzheimer's disease, nicotine can prevent brain plaque
formation, which is considered to be involved in pathogenesis of the disease (Wang
et al., 2000). Nicotine has also been shown to improve cognitive and motor
functions in Parkinson's disease by triggering dopaminergic neurons and protecting
them from damage and loss. (Kelton et al., 2000) Smokers have a lesser incidence
of Parkinson's than non-smokers (Morens et al., 1995).

The possible

neuroprotective effects of nicotine have just begun to be examined in the retina and
may have promising results in neurotoxicity models.
Recently in this lab, ACh and nicotine have been shown to prevent
glutamate-induced excitotoxicity through al and a4p2 nicotinic acetylcholine
receptors in isolated adult pig RGCs (Wehrwein et al., 2004; Thompson et al., 2006).
There are several pathways that can ultimately lead to apoptosis or can protect cells
from apoptosis. In the CNS, activation of nAChRs has been shown to protect
against a and P amyloids, which are involved in Alzheimer's disease through several
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neuroprotective pathways such as pathways that involve Janus Kinase2 (JAK2) or
phosphoinositide 3-kinase/akt (PI3K-AKT) (Shaw et al., 2002; Buckingham et al.,
2009).

Studies from the Linn lab have demonstrated that activation of ACh

receptors activate a second messenger system that increases cell survival via 2
pathways. ACh receptor activation leads to up-regulation of PI3 kinase-Akt-Bcl2 to
enhance cell survival, and simultaneously decreases the p38 MAP kinase pathway
that is involved in glutamate-induced apoptosis in this system (Asomugha et al.,
2010). The link between ACh receptor activation and activation of cell survival
pathways in the cultured pig RGC system was found to be calcium influx through
the nAChR channels (Brandt et al., 2010). In this proposed study, I will perform
experiments designed to determine if pretreatment of retinal tissue with an al
agonist before inducing glaucoma will provide neuroprotection and prevent loss of
cells from the RGC layer.

Previous studies

The initial glutamate excitotoxicity and ACh neuroprotection work in the
retina came from the Wehrwein et al. (2004) study where isolated pig RGCs were
used to determine what receptors were involved in glutamate excitotoxicity, as well
as to determine if ACh provided neuroprotection against excitotoxicity. This study
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also developed a method of isolating the RGCs to use as an in vitro model of
excitotoxicity and glaucoma. In this study, a technique first proposed by Barres et al.
(1988) was modified to purify the RGCs from other retinal tissue. This technique
involved using anti-rabbit IgG antibody to remove non-specific binding and an antigoat IgM antibody with an antibody against Thy 1.1, a glycoprotein specific for
RGCs in the retina, to isolate them from all other retinal tissue. This 2 step isolation
method isolated pure RGCs, which were cultured and treated with various
pharmacological agents.
In the study by Wehrwein et al., (2004), glutamate and other glutamate
receptors agonists, such as NMDA and KA, were used to determine what receptors
were involved in cell excitotoxicity. The experiments with glutamate using different
culture time intervals suggested that a chronic exposure of 500uM glutamate over 3
days resulted in over 40% of RGC death.

These studies also demonstrated that

glutamate affected both large and small RGCs. Glutamate excitotoxicity was found to
be mediated through both NMDA and non-NMDA receptors. These results were
confirmed using a competitive NMDA antagonist, AP-7, and a noncompetitive
NMDA antagonist, MK-801.

When cells were pretreated with these glutamate

antagonists, the excitotoxic effects were eliminated.
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The other experiments performed in the study by Wehrwein et al. (2004)
explored the potential neuroprotective effects of ACh against glutamate-induced
excitotoxicity and determined what ACh receptors were responsible. When ACh was
preapplied to the RGC culture 2 hours prior to glutamate application, the glutamate
excitotoxic effects was eliminated and cell survival was near control levels. To
determine if this effect was through nicotinic or muscarinic receptors, nicotine and
muscarine was used in similar experiments.

At low concentrations of nicotine,

neuroprotection against glutamate-induced excitotoxicity occurred but there was no
neuroprotection associated with activation of muscarinic ACh receptors, which
indicated the neuroprotective effect was through nAChRs.

When the nicotinic

antagonist, a-Bgt, was applied before ACh or nicotine, the neuroprotective effect of
ACh and nicotine was significantly reduced.

This supports the hypothesis that

neuroprotection was mediated by nAChRs. a-Bgt is an antagonist for the a7 receptor
but can also bind to other subtypes of nAChRs at high concentrations and did not
provide enough evidence that ACh-induced neuroprotection in pig RGCs was
mediated through just a7nAChR. To explore this, MLA, an antagonist specific for
the a7 receptor at l-10nM, was used to determine if nicotine and ACh's
neuroprotective effect was affected. When MLA was applied before ACh or nicotine,
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a significant reduction in cell survival was observed. The use of MLA confirmed that
ACh's neuroprotective effect was partially mediated through a7nAChRs.
This study raised further questions about neuroprotection in the retina.
Though a7AChR were shown to play an important role, were other receptors within
the nAChR family involved as well? The Thompson et al. (2006) study done in this
lab further explored other possible neuroprotective targets using the pig retina.
In the CNS, besides the homomeric a7nAChR subunits, there are heteromeric
types, which contain a combination of a and p subunits.

For instance, functional

AChR channels that are composed of (a3)2(P4)3 and (a4)2(P2)3 subunits are both
functional types of nAChR channels that can be found in the brain (Le Novere et al.,
1995).

These subunits may exist in the retina, and could be involved in the

neuroprotective effect, which could explain why only a partial effect was seen using
an a7 antagonist.
To determine if different subunits could be found on pig RGCs, monoclonal
antibodies against the a4, P2, a7 ACh subunits were used and labeled using
fluorescent secondary goat anti-rat antibody.

Double-label experiments were

performed staining the as a4 subunits with Alexa-fluor 488 while the P2 subunits
were stained with Texas red. a4 and P2 subunits typically form functional channels
in the brain Thompson et al., 2006). The results showed that both a4 and P2
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subunits exist on RGCs. However, results also demonstrated that these specific
subunits can be found only on the small parvocellular RGCs. In the pig, the
a7nAChR subunits, exist exclusively only on large magnocellular RGCs (Thompson
et al, 2006).
Pharmacological studies were performed to determine if activation of the
(a4)2(P2)3 nAChR subtypes had a neuroprotective effect against excitotoxicity. The
methods used in the Wehrwein study were used with different agonists for specific
ACh subtypes. Agonists specific for the a4 receptor were tested, including anatoxin,
UB 165 fumarate, RJR 2403, lobeline hydrochloride, and epibatidine. Each of these
a4

agonists

provided

partial

neuroprotection

against

glutamate-induced

excitotoxicity. This result was confirmed when the a4 nAChR antagonist, DihydroP-erythroidine hydrobromide (DHbE) was applied to cells before ACh and glutamate.
In the presence of this antagonist, DHbE significantly reduced ACh's
neuroprotective effect when applied to small RGCs before ACh and glutamate but
had no effect on the large RGCs. Thus, both a7 and a4 nAChR activation was found
to be involved in ACh induced neuroprotection in the pig retina.
These experiments identified what nAChRs are found on pig RGCs, as well as
what receptors trigger neuroprotection. The next experiments done in the lab were
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designed to examine the mechanism involved in ACh-induced neuroprotection in pig
RGCs.
In the CNS, activation of metabotropic receptors has been clearly linked to
triggering different kinase enzymes to produce a physiological response. However,
neuroprotection in pig RGCs did not occur through activation of metabotropic
receptors. Instead, previous pig studies from this lab have shown that neuroprotection
was caused by calcium influx through nAChR channels on RGCs that initiate cell
survival pathways and inhibit apoptotic pathways (Asomugha et al., 2010; Brandt et
al.,2010).
The apoptotic and cell survival enzymes involved with glutamate-induced
excitotoxicity and ACh-induced neuroprotection in pig RGCs were examined using
ELISA techniques to quantify and measure protein content of the enzymes involved in
neuroprotection and apoptosis (Asomugha et al., 2010). Two enzymatic pathways
were identified from these studies. p38 mitogen-activated protein kinase (MAPK)
levels were upregulated during glutamate-induced excitotoxicity and involved with
apoptosis induced by neurotoxicity. ACh affected two different pathways to induce
neuroprotection. In the presence of ACh, the phosphatidylinositol 3-kinase (PD)-Akt
pathway was triggered to enhance cell survival while p38-MAP kinase levels
involved in the apoptotic pathways were reduced (Asomugha et al., 2010). Further
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calcium imaging studies by Brandt et al. (2011), demonstrated that calcium
permeation through nicotinic channels initiated the intracellular cascades.

PNU compounds

Two compounds used in this study, PNU-282987 and PNU-120596, are
specific ligands that bind to the a7nAChR. PNU is an acronym for Pharmacia and
Upjohn, the company where these drugs were developed and analyzed.

These

specific agents that bind to a7nACh receptors will be used in an in vitro model of
toxicity and in an in vivo model of glaucoma in Long Evans rats.
PNU-282987 is a compound discovered by Pfizer using a high-throughput
process which utilizes robotics and automated systems to test millions of drugs
genetically and biochemically.

Binding studies with rat chimera cells and

electrophysiology studies in rats have demonstrated that PNU-282987 is a potent
specific agonist for a7nAChRs (Bodnar et al., 2005). These binding studies have
shown that PNU-282987 can displace MLA, an a7 antagonist. Using rat hippocampal
neurons, application of the PNU compounds cause currents through a7nAChR
channels in a dose dependant matter. This effect was blocked with MLA (Bodnar et
al., 2005). As a result of these previous studies, this a7nAChR specific agonist will
be used in this study to understand the role of the a7nACh receptor in rat eyes without
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worrying about cross reactivity or cross binding with other nAChRs that may make
the analysis and interpretation of data difficult.
PNU-120596 is another specific a7 compound that has been screened using
the high-throughput process by Pfizer and tested in electrophysiological experiments.
PNU-120596 acts as an allosteric modulator at the a7 receptor and binds to a different
site than the agonist (Hurst et al., 2005). It has been suggested that nicotinic receptors
have neuroprotective effects against retinal diseases including glaucoma (Wehrwein et
al., 2004). However, with receptor desensitization, which is characteristic of nicotinic
channels, prolonged exposure to a specific agonist may not be effective.

PNU-

120596 however, not only increases potency and maximal effects of the agonist alone,
electrophysiology studies have shown that it prolongs the current as well (Hurst et al.,
2005). This compound has not previously been tested in the retina, but has shown
potentiation of responses from studies using brain slices (Livingstone et al. 2009) In
this proposed study, I plan to use this compound in conjunction with the specific
a7nAChR agonist to enhance and/or prolong the neuroprotective effect against
excitotoxicity, and to determine the effects of these PNU agents in an in vivo
glaucoma model.
With these a7nAChR specific compounds, I will be able to identify the
neuroprotective effects of stimulating the a7nAChRs in the rat retina, as well as
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analyze modulation of a7 nicotinic receptors in an in vitro and in vivo model of
excitotoxicity and glaucoma respectively.

METHODS

Animals

Adult male and female Long Evans rats (breeding colony, WMU) were used
for these experiments.

Long Evans are docile by nature and have prominent

eyeballs, thus making the surgical manipulations easier to perform than other rat
strains.

Each animal was kept in the animal colony prior to experiments and

handled daily 1 week prior to surgery to minimize discomfort. All animals were
treated and eventually euthanized according to IACUC protocol at WMU.

In vitro studies

Preparation
Before obtaining retinas from Long Evans rats, 8 welled glass chamber slides
used in these experiments were precoated using poly-1-lysine and laminin. Briefly,
0.1 mg/ml of poly-1-lysine was added into each chamber and incubated at 37°C with
5% C 0 2 overnight. The next day, the slides were washed with H 2 0, dried and treated
with 10 ng/ml laminin overnight.
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After slides were prepared, eyes were removed from Long Evans rats
euthanized with C0 2 . The remaining euthanized rat carcasses were placed in a freezer
until disposed of through the animal care facility at WMU. The removed eyeballs
were briefly dipped in 70% EtOH and the cornea and lens were carefully removed
from the eye to create an eyecup. The retina was scraped off from the back of the
eyecup using a flattened spatula after cutting the optic nerve.

To begin the

dissociation of the retina, the removed retina was incubated in a papain solution
containing 2mg/ml papain (Sigma), 0.4mg/ml DL-cysteine (Sigma) and 0.4 mg/ml
BSA (Sigma) in Neurobasal medium (Gibco/Invitrogen) for 25 minutes at 37°C, then
washed 3 times with RGC culture medium. The RGC culture medium contained
Neurobasal/B27 medium (Gibco) containing lOOunits/mL penicillin (Sigma), 100
ug/mL streptomycin (Sigma), ImM pyruvate (Gibco/Invitrogen), 2mM glutamine
(Gibco/Invitrogen), 5p.g/mL insulin (Sigma), 100 ug/mL transferrin (Sigma),
lOOug/mL bovine serum albumin (Sigma), 60ng/mL progesterone (Sigma), 16ug/mL
putrescine (Sigma), 40ng/mL sodium selenite (Sigma), 40ng/mL thyroxine (Sigma),
40ng/mL tri-iodothyronine (Sigma), 50ng/mL BDNF (Biosource, Camarillo, CA),
lOng/mL CNTF (Biosource), lOng/mL bFGF (Biosource), 5uM forskolin (Sigma),
and 1% fetal calf serum (Atlas Biologicals, Fort Collins, CO) (Pang et al., 2007).
After papain treatment, cells were mixed with lOmls of culture medium and the retina
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was further dissociated by trituration with a glass pipette. The retinal tissue was then
evenly divided into precoated 8 chamber welled slides at a density of 5 x 106 cells/ml,
treated with various pharmacological conditions and incubated at 37°C in 5% C0 2 .
During the plating procedure, great care was taken to ensure that the dissociated retina
was evenly distributed between culture wells so that each culture well contained the
same number of cells at the beginning of the culture procedure. To do this, all
dissociated cells were pooled together and continuously mixed while 200u1 of evenly
dispersed cells were plated into each well. Once the cells were evenly distributed into
precoated chamber-welled slides, they were treated with various pharmacological
agents and cultured at 37°C in 5% C0 2 condition for 3 days. The a7 nicotinic agonist,
PNU-282987, and modulator, PNU-120596, was added 1 hour prior to the glutamate
treatment. The antagonist, MLA, was added 1/2 hour prior to PNU-282987. The
application and duration time that produced maximal effect of each pharmacological
agent was worked out from preliminary studies. Concentrations that produced the
greatest effects were used in these studies.
After 3 days of incubation, the cells were fixed with 10% formalin for 30
minutes and then rinsed 3 times in PBS. After rinsing, fixed RGCs were incubated
with a primary monoclonal antibody against Thy 1.1 (Chemicon) in 0.02% saponin
and PBS at a final dilution of 1:500. Thy 1.1 is a glycoprotein found only on RGCs
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and was used as a specific marker for RGCs (Barnstable and Drager, 1984). The
slides were placed in a humidified chamber overnight in 4°C.
The following day, the slides were rinsed 3 times to remove the primary
antibody. To visualize the cells, the cells on the slides were incubated with a
fluorescently labeled secondary antibody Alexa-Fluor 594 goat anti-mouse IgG
antibody at 1:300 dilution. (Invitrogen/Molecular Probes) for 30 mins and rinsed
with water. The well walls of the chamber slides were removed and cells were
mounted on the glass slide using a mixture of 50% glycerol and 50% PBS mounting
medium.
In other in vitro studies, cholinergic amacrine cells were stained with an
antibody against choline acetyltransferase (ChaT), which is an enzyme required for
ACh synthesis. In the retina, only cholinergic amacrine cells stain with ChaT. The
culture was fixed using 10% formalin for 30 minutes and then rinsed 3 times in PBS.
The cells were then placed in the polyclonal primary goat anti-rat antibody for ChaT
(Millipore) diluted to 1:100 in 0.4% Triton-X in PBS overnight in 4°C. After 3
subsequent rinses with PBS, the cells were secondarily labeled with Alexa-Fluor 388
donkey anti-goat IgG (Invitrogen) diluted to 1:500 in PBS (Bhagwandin et al., 2006).
In separate experiments, to determine the specificity of the antibodies, cells were
processed and incubated without primary antibody. When the primary antibody was
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omitted, no staining was observed.
The method of immunostaining RGCs in rat retina was modified from the
Wehrwein study (2004) where Thy 1.1 antibody was used in an isolated RGC
culture. In my rat study, the RGCs were not isolated from other retinal tissue, but all
retinal tissues were dissociated and incubated together. However, Thy 1.1 antibody
was later used to specifically tag RGCs for identification. All rat retinal tissues were
dissociated and cultured together to increase the viability of RGCs as the amount of
retinal tissue obtained from each rat eye was much less than the amount of tissue
obtained from each pig eye. We found that isolating rat RGC using the 2 step
panning procedure before culturing did not produce a high enough density of cells
for RGC survival in the rat unless large numbers of rat eyes were used in each
experiment. Therefore, we modified the culture condition in the rat system so RGCs
were cultured with other retinal tissue.
Microscopy was performed using the Nikon Diaphot epifluorescent research
microscope illuminated by a 100-W mercury arc lamp with appropriate excitation
wavelengths. Four pictures were taken from each cultured well (top, bottom, left
and right section of each well) from the same locations. Images were captured using
the Hamamatsu XC-77 CCD camera and Metamorph Imaging system (Universal
Imaging). Based on size and intensity, the fluorescently labeled RGCs were divided
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into large and small RGCs, counted and averaged. The number of cells that were
treated pharmacologically was compared to the number of cells incubated under
untreated control conditions obtained from each internal control. Data was always
normalized to the internal controls from the same animal. In some studies, RGC
counts were normalized based on percent of cells compared to control.

In vivo studies

Inducing glaucoma
Before surgery to induce glaucoma, adult Long Evans rats (aged 3-6 months;
males and females) were anesthetized with O.lml/lOOg KAX via intraperitoneal
injections until no reflexes were observed. KAX is a combination cocktail consisting
of 5 ml ketamine (100 mg/ml), 2.5 ml xylazine (20 mg/ml), 1 ml acepromazine (10
mg /ml), and 0.5 ml sterile water.
The method to induce glaucoma is based on Morrison's method of injecting
2M hypertonic saline into the episcleral vein of the eye (1997). The 2M salt solution
causes scarring in the trabecular meshwork and decreases the outflow of aqueous
humor.

This results in a gradual increase of intraocular pressure, mimicking

glaucoma-like conditions. A topical anesthetic of 0.5% procain hydrochloride was
applied to the eye before the surgery to induce glaucoma. To expose the targeted
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episcleral veins and to restrict movement of the eye, a hemostat was used to pinch
the bottom eyelid, which caused the eye and corresponding episcleral veins to bulge.
The conjunctiva was incised with a fine scissors to further expose the vein, under a
25X to 40X magnification. To inject 50 ju.1 of 2M hypertonic saline into the right
episcleral veins, a 3mm long glass microneedle, 30 to 50 um in diameter, was glued
onto a tapered polyethylene tubing (PE-50, Clay Adams, Parsippan, NJ). The
microneedle was inserted into a 23 gauge needle with the tip filed off, and attached
to a 1ml syringe.

The glass needle was made using a Sutter horizontal

microelectrode puller. When the salt was injected into the right episcleral veins, the
anterior chamber of the eye turned white, which acted as verification that the salt
made it into the circulatory system of the eye. Blanching of the anterior chamber
was always associated with loss of cells from the RGC layer within a month.
Additional doses of KAX were administered if any involuntary movements were
observed during surgery. The rats were confirmed to be fully awake with no
irregular effects before they were transported back to the animal colony. Injections
of 2M hypertonic saline were always performed on the right eye in each rat. The left
eye for each rat was left untreated and acted as an internal control.

39

Histology

One month following the glaucoma-inducing treatment, rats were
anesthetized and euthanized by decapitation before the control and glaucomainduced eyes were removed. The cornea and lens were subsequently cut away. The
retinas at the back of the eyecups were carefully removed in one piece from each
eye and 4 incisions at every 90 degrees were made in order to flat mount the retinas
onto small sylgard plates using cactus needles. Pinned out retinas were then fixed
with 4% paraformaldehyde overnight. Once fixed, the retina were transferred to a
pig skin gelatin-coated glass slide and the standard Nissl (cresyl violet) procedure
was used to stain cell nuclei. During this procedure, the retinas were washed with
ascending concentrations of ethanol, stained with cresyl violet and further dried for
mounting with DPX mounting medium.
Once mounted, the stained tissues were viewed throughout the ganglion cell
layer using 1 micron increments using the capabilities of a confocal microscopy with
a rhodamine filter. This process gives good contrast between RGCs and background,
allowing for easy quantification.

Cell bodies were opaque and could easily be

counted. The stained cells were counted using Metamorph software.

In some

experiments cell counts were normalized to the internal control for each animal by
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comparing the average counts from samples of both conditions.
Figure 4 depicts an image of the flat mounted retina. Using the optic nerve
head as a visual landmark, 8 series of images were obtained using the lOx objective
with the confocal microscope. Images were obtained from the top of the RGC layer
through the entire RGC layer using 1 micron increments. The top layer that was in
most focus within the series of photos was used. In each quadrant, one series of
images were obtained from the periphery (red squares) of the retina at 400ums from
the optic nerve head (ONH) and the 2nd series of images were obtained at 200 um
from the ONH (yellow circles).
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Figure 4: Flat mounted retina
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The retina stained with cresyl violet and regions photographed using the Zeiss
confocal microscope. The yellow circles indicate 200 um from the optic nerve head
(ONH) red squares indicate 400|im from the ONH.

Figure 5 depicts low power images obtained from the periphery in a control
untreated eye (fig. 5A) and a glaucomatous eye from the same animal (fig. 5B).
Surgery to induce glaucoma was performed one month before the retinas were
removed, stained with cresyl violet and visualized using the confocal microscope.
The glaucomatous eye (fig. 5B) had significantly lower cell density then a control
eye and fewer defined axon tracts.

Figure 5: Visualization of cell loss from the in vivo glaucoma model
Stained retina was removed from the eye and flat mounted onto a sylgard plate. (A)
is an image from a control eye and (B) is taken from a hypertonic saline injected eye.
Both images were taken from a control untreated and an experimental eye from the
same rat. Images obtained from both eyes were obtained from the same depth in the
RGC layer and from the same region of the retina. Arrows point to defined axon
tracts.
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The number of stained cells in the RGC layer were counted at both distances
and compared. The bar graphs in fig. 6 summarize the results of these experiments.
Each bar graph represents the average number of stained cell bodies counted from
the periphery and proximal RGC layer. The peripheral part of the retina had an
average of 27.35% (+/-2.12) cell loss 1 month after injecting 2M NaCl hypertonic
saline, compared to the proximal distance which had an average of 20.01% (+/5.21) cell loss (Fig 6). As more cell loss in the periphery is typically associated with
glaucoma, all other experiments counted cells 400 um from the ONH.
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Figure 6: Percent cell loss associated with glaucoma-inducing procedure
This graph depicts the percent survival of cells in the RGC layer in both proximal
and distal distances from the ONH 1 month after surgery to induce glaucoma. Each
bar was produced using between 6 and 9 rat eyes. * represents significance from
internal controls. Error bars represent SEM from 1 way-ANOVA.
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To determine the timeline for the glaucoma model, animals were euthanized
at 1 month, 2 months and 3 months following the hypertonic injections. At 1 month
intervals, the retina were carefully removed and flat-mounted onto a sylgard plate
with cactus needles, fixed and cells in the RGC layer were stained with cresyl violet.
Cell counts were obtained from the periphery in experimental eyes and compared to
cell counts obtained from the periphery in internal control eyes.

As can be seen by

the summarized results in fig. 7, significant loss of cells in the periphery of the RGC
layer occurred 1 month following the surgery and there was no additional significant
difference in the loss of cells at 2 and 3 months compared to 1 month results.
Though longer studies were done at 4 and 6 months, (data not shown), at 1 month,
hypertonic injections of saline into the episcleral vein always caused a significant
amount of cell loss in the RGC layer if blanching occurred in the anterior chamber
following the injection (p<0.05).

Based on these results, all rats in subsequent

glaucoma-inducing experiments were sacrificed 1 month following surgery to
induce glaucoma and cell counts were obtained 400 urn from the ONH.
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Figure 7: Cell loss associated with the glaucoma procedure at various time
points
Animals were euthanized at different time points after surgery to induce glaucoma
and the loss of cell in the RGC layer were quantified in a time-dependent manner.
Each bar graph represents the average number of retinal cells that were counted in
the RGC layer after inducing glaucoma with hypertonic saline injections.

(*

indicates significance from the untreated control). Each bar graph was generated
from between 3 to 9 experiments. Each experiment used 3 rats and were repeated a
minimum of 3 times. Error bars represent SEM.

Intravitreal injection of pharmacological agents

For all in vivo studies, drugs were injected intravitreally in volumes of 5 pi
using a 5ul Hamilton syringe. The injections of various pharmacological agents
included the a7 nicotinic agonist, PNU-282987, the a7 modulator, PNU-120596, and
the a7 antagonist MLA. These agents were injected into the eye before surgery that
normally induces glaucoma according to the timeline obtained from rat in vitro
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studies.

Data analysis

All cell counts were compared to the internal control counts for each
experiment. Student T-tests were used for single comparisons, and one-way ANOVA
was used for multiple comparisons to statistically measure cellular loss with Tukey
posthoc tests using Graphpad statistical software and minitab. For normalized data,
statistical analysis was performed using Kruskall-Wallis non parametric analysis of
variance with post hoc comparisons (Dunn's test). A p-value of < 0.05 (95%
confidence) represents significance.

Graphs were plotted with Prism GraphPad

version 4.0 software (GraphPad Software, Inc., San Diego, CA)

RESULTS

In vitro studies

Glutamate excitotoxicity
To determine if the glutamate excitotoxic effects that were observed in pig
studies are also demonstrated in rats, rat retinas were cultured for 3 days with
500uM glutamate, lOOuM kainic acid (KA), lOOuM 7V-Methyl-D-aspartate
(NMDA), or with a combination of KA and NMDA. When glutamate alone was
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applied (Fig. 8B), an average of 45.21% (SE ±2.10) cell reduction was observed
compared to control untreated RGCs (Fig. 8A). However as seen in figure 8C, when
the cultured cells were incubated with the KA receptor antagonist, CNQX (lOuM)
and the NMDA antagonist MK801 (lOOuM) for 30mins before applying 500uM
glutamate, the toxic effect of glutamate was eliminated. This suggested that KA and
NMDA glutamate receptors are involved in glutamate's excitotoxic effect.

Figure 8: Effects of glutamate on cultured RGCs
After 3 days in culture, RGCs were fixed and stained with an antibody against Thy
1.1. and labeled with Alexa-Flour 595 for visualization. Glutamate caused obvious
RGC loss, and the RGC loss was blocked by CNQX and MK-801. Images were
obtained after 3 days in culture under the various pharmacological conditions: (A)
control untreated conditions (B) cultured for 3 days with 500uM glutamate, and (C)
pretreated with both MK-801 and CNQX before application of 500uM glutamate.
Arrows indicated stained RGCs.

The bar graphs shown in fig. 9 demonstrate that both KA and NMDA had
negative effects on RGC survival when applied 30mins before 500uM glutamate.
KA reduced cell survival by an average of 32.33%) (SE ±2.19) while NMDA reduced
RGC survival by an average of 21.28% (SE ±4.03) when applied before glutamate.
However, when a combination of KA and NMDA was applied to the cells before
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glutamate, the RGC loss observed were similar to glutamate alone, by decreasing
cell survival by 46.23% (SE ±3.54). The RGC loss due to the pretreatment with a
combination of NMDA and KA was eliminated if glutamate receptor antagonists,
consisting of lOuM CNQX and lOOuM MK-801, were applied before the glutamate
agonist cocktail (Fig 9). These results provide evidence that glutamate-induced
excitotoxicity of rat cultured RGCs is mediated through both KA and NMDA
glutamate receptors similar to results obtained in pig retina.
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Figure 9: RGC loss due to glutamate agonists
Each bar graph represents the average numbers of RGCs that survive after 3 days of
culture with various pharmacological treatments. A significant decrease in cells was
observed when the cells were cultured with 500uM glutamate. Partial toxic effects
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were observed when RGCs were incubated with KA or NMDA separately. However
when both glutamate agonists KA and NMDA were applied to the culture together,
the amount of cell death mimicked the effect of glutamate alone. A combination of
KA and NMDA receptor antagonists, CNQX and MK-801 respectively, blocked this
effect. Averages were obtained from between 6-9 animals. * represents significance
from control. # represents significance from glutamate's effect. Error bars represent
SEM.

Glutamate excitotoxicity was also tested at different time points. When cells
were cultured in 500uM glutamate for 1, 3, 5 and 7 days, a significant decrease in
cell survival was observed by day 3 (Fig. IOC). When separating glutamate effects
by large and small RGCs, it was found that both types of RGCS were prone to
glutamate damage.

Glutamate significantly reduced the number of both types of

RGCs after 3 days in culture (Fig. 10A, Fig. 10B). As a result, all future in vitro
experiments cultured cells for 3 days before assaying for cell survival. One thing to
note is that the in the control untreated conditions, the large RGC had loss of cells
presumably due to cell death associated with the culturing process, where the small
RGCs were more resistant to that cell loss after 7 days.
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Figure 10: Glutamate excitotoxicity timeline
Glutamate causes a decrease in RGC survival in a time-dependent manner in both
large and small RGCs. Solid circles represent the percent survival of RGCs after
various amounts of time in culture under control untreated conditions. Solid squares
represent percent survival of RGCs at various time points after being cultured with
500uM glutamate. (A) Percent cell survival for cultured large RGCs. (B) Percent cell
survival for cultured small RGCs and (C) Percent cell survival for all RGCs pooled
together. * Represents significance from glutamate. Normalized data points were
obtained from a minimum of 3 experiments. Each experiment used tissue from 3 rats.
Error bars represent SEM.
ACh neuroprotection

When rat RGCs were cultured with lOuM ACh or lOOuM nicotine, both
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compounds resulted in higher cell counts compared to glutamate conditions. The
results of these experiments are summarized in Fig 11. As shown by the bar graphs
in figure 11, when lOOuM nicotine or 10 uM ACh was applied 1 hour before 500pM
glutamate, glutamate excitotoxicity was eliminated. Both lOOuM nicotine and 10
uM ACh produced the maximal cell against glutamate-induced excitotoxicity based
on dose-response studies. lOOuM nicotine increased cell survival by an average of
104.47% (SE ±7.062) compared to control conditions, while lOuM ACh increased
cell survival by an average of 113.88% (±11.46) compared to the control untreated
condition. However, when the a7 nicotinic antagonist MLA (lOnM), was applied to
cultures of rat retina before ACh and nicotine and the glutamate insult,
neuroprotection was not observed. In the presence of MLA, ACh and nicotine had
no significant neuroprotective effect against glutamate-induced excitotoxicity.
These results were consistent with the results obtained from previous pig studies
(Wehrwein et al. 2004) and support the hypothesis that neuroprotection against
glutamate-induced excitotoxicity is mediated through a7nAChRs on rat RGCs. To
further

support this hypothesis, the next experiments used the specific

a7nAChRagonist, PNU-282987.
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Figure 11: Effects of ACh and nicotine on rat RGCs (in vitro)
Each bar represents the average percent of RGCs that survive compare to control
untreated conditions. Both nicotine and ACh provided significant neuroprotection
against glutamate excitotoxicity. When the lOnM a7 nicotinic antagonist MLA was
applied at 30mins before ACh and nicotine, the cell survival significantly decreased.
# represents significance from glutamate's effect and * represents significance from
control untreated conditions. Experiments were repeated between 3 and 9 times.
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Effects of an a7 ACh agonist in vitro

To determine if the specific a7 ACh agonist, PNU-282987, has
neuroprotective effects against glutamate-induced excitotoxicity in cultured rat
retina, retinas were dissociated and cultured after pretreatment with various
concentrations of PNU-282987 for 1 hour before addition of 500 uM glutamate.
After 3 days, RGCS were fluorescently labeled with an antibody against Thy 1.1.
Figure 12 represents sample images of RGCs fluorescently labeled with an antibody
against Thy 1.1. Fig. 12A was obtained from retinal tissues cultured for 3 days
under untreated control conditions. Fig. 12B represents an image obtained when the
same density of retinal tissue was cultured for 3 days in the presence of 500uM
glutamate. When PNU-282987 was applied before glutamate, higher cell survival
was observed (Fig. 12C), but when the RGCs were pretreated with lOnM MLA
before PNU-282987 and 500uM glutamate, the cell survival was significantly
reduced (Fig 12D, Fig. 14).
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Figure 12: Effects of PNU-282987 in vitro
PNU-282987 provides neuroprotection against glutamate-induced excitotoxicity.
Images of labeled RGCs were obtained after 3 days in culture under the following
conditions: (A) under control untreated conditions. (B) in 500uM glutamate. (C)
pretreated with PNU-282987 for 1 hour prior to 500uM glutamate and (D) when the
specific a7 antagonist, MLA (lOnM), was applied 30 minutes prior to PNU-282987
and 11/2 hours prior to 500 am glutamate.

Pretreatment of cells with lOOnM of PNU-282987 before glutamate
application produced the greatest survival of large RGCs suggesting that PNU282987's effects are dose dependent. As shown in the summarized data shown in fig.
13, when lOnM, luM or lOuM PNU-282987 was applied before glutamate, there was
no significant cell survival effects. At lOuM PNU, a significant decrease in cell
survival occurred, compared to glutamate's effect, which was likely due to nonspecific effects associated with this relatively high concentration used (Fig. 13).
54

150-1

#

O 100O
OH

"5
*

#

50-

I

^

J?

o°*

^'
#

^

^

rP'

^
N-

rfF

V

«**

K

«#'

W *&
« *

<**
^

^

«5?%

r

^

H
500 |JM Glutamate

Figure 13: Dose dependent effects of PNU-282987 on cells in the RGC layer
Bar graphs represent the average number of labeled RGCs counted after culturing
them for 3 days with different concentrations of PNU-282987 and 500uM glutamate.
PNU-282987 was applied one hour before the glutamate insult. * indicates
significance from control. # indicates significance from glutamate conditions
(PO.05). Averages were obtained from N's of 3-9.

In other experiments designed to provide evidence of a7nAChRs in
neuroprotection, the cell culture was pretreated with MLA, an antagonist specific to
the a7 receptors. In the presence of lOnM MLA, PNU-282987 had no effect on
glutamate-induced excitotoxicity (Fig 14).
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Figure 14: PNU agonist's neuroprotective effects
lOOnM of PNU-282987 provided neuroprotection against glutamate. When MLA
was injected into eyes before the PNU compound, the PNU-induced neuroprotection
was blocked. (* indicates significance from control. # indicates significance from
glutamate conditions). Averages were obtained from between 6 and 9 experiments.

In pig studies, the a7nAChR were only found on large RGCs. To determine
if this is also true in rats RGCs, the effect of the a7 agonist was also compared in
large and small populations of the RGCs. Figure 15 represents the effects of
glutamate and the PNU a7 agonist over a 3 day time period on large and small
RGCs. In both the large and small RGCs, glutamate had an excitotoxic effect and
significantly decreased RGC numbers by the 3rd day. The small RGC were slightly
more resistant to the glutamate damage compared to large RGCs. However, while
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the large RGCs demonstrated a gradual decrease in the control untreated conditions
presumably due to the dissociation process, the percent of small RGC population did
not significantly decrease by the 3 rd day in control untreated conditions. Therefore,
the small RGCs were more resistant to cell loss due to the dissociation and culture
conditions.
Application of PNU-282987 protected the large RGCs and the cell survival
was similar to the control levels (Fig 15A). PNU-282987 also had neuroprotective
effects on the small RGC population (Fig 15B), although it did not provide complete
neuroprotection against glutamate-induced excitoxicity in small RGCs like it did in
large RGCs (Fig 16).

However, these results suggest that unlike pig studies,

a7nAChR may be found on both large and small RGCs in rats. Certainly, in rat the
small RGCs show a response to these compounds presumed to interact specifically
with a7nAChR.
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Figure 15: Effects of PNU-282987 on large and small RGCs
PNU-282987 caused an increase in the percent of RGC survival in both large and
small RGCs if applied to cultures one hour before 500uM glutamate. Each normalized
data point represents the percentage of cells that survived compared to control
untreated conditions at Day 0. Each bar represents the percent survival of RGCs after
three days in culture. A) Percent cell survival for cultured large RGCs. B) Percent
cell survival for cultured small RGCs C) Percent cell survival for all RGCs pooled
together # represents significance from glutamate, * represents significance from
control. Normalized data points were obtained from between 6-9 rats. Error bars
represent SE.
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In vivo studies

Effects of PNU agonist in vivo
The objective of the next experiment was to determine if the neuroprotective
effects seen using the in vitro excitotoxic model can be observed in an in vivo model
of glaucoma. The vitreous in the right eye of each rat was injected with 5ul of
lOOuM PNU-282987 1 hour before the hypertonic saline injection. Figure 16
represents sample images obtained during these experiments. One month after
hypertonic saline was injected to induce glaucoma-like conditions, a significant
amount of cell loss in the RGC layer was observed (Fig. 16B) compared to control
retinal images obtained from the internal control eye (Fig. 16A). In addition, the
defined axon tract characteristics in control retinas (arrows; fig. 16A) are fragmented
in the peripheral retina under experimental conditions (arrowheads; fig. 16B).
However, when the a7 agonist, PNU-282987, was injected into the eye before the
hypertonic injection to induce loss of cells in the RGC layer, the decrease in cell
survival was eliminated (Fig. 16D) and cell counts were similar to control cell
counts obtained from the internal control (Fig. 16C). In addition, if PNU-282987
was injected before surgery to induce glaucoma, the defined axon tract remain intact.
However when lOnM MLA was injected before the PNU agonist, neuroprotection

59

against cell loss did not occur, as seen when comparing panels E and F. Panels G
and H are images obtained from a sham study where 5|rl of PBS was injected into
the vitreous (Fig. 16H) before the glaucoma inducing surgery. G represents the
internal control from the same animal. As demonstraed in panel H, the injection
itself was not sufficient enough to prevent loss of cell in the RGC layer and is not
sufficient to prevent loss of defined axon tracts. All of these experiments that
produced images for fig. 16 were repeated between 3 and 9 times with similar
results.
The summary of the in vivo experiments using PNU-282987 are illustrated
in the bar graphs shown in figure 17. After injection of hypertonic saline into the
episcleral veins, there was an average loss of 23.86% (SE±6.68, n=8) in the RGC
layer. However, when retinas were pretreated with the a7 nAChR agonist PNU282987, the cell death associated with the saline injection was eliminated and cell
counts in the RGC layer in the periphery were statistically the same as in control
conditions. When MLA was injected prior to the PNU agonist and surgery, the
neuroprotective effect of PNU was eliminated and a significant loss of cells from the
RGC layer occurred.
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Figure 16: Sample of in vivo images with and without PNU agonist
The left columns represents the internal control images obtained from the same rat
that the right column images in the same row were obtained from. B: image
obtained after 2M hypertonic injection into eye. Arrow represent axon tracts and
arrow heads represents cresyl violet stained retinal cells. D: 50 u.1 of 100 uM PNU282987 injected into eye 1 hour before surgery to induce glaucoma. F: 10 nM MLA
was injected into eye before PNU agonist and before surgery. H: PBS was injected
61

into eye before surgery to induce glaucoma. Scale bar is equal to 50pm.

In sham experiments, 5 pi of PBS vehicle was injected into the eye before the
glaucoma surgery to determine if the surgery alone was responsible for the increase
of cell survival. The sham treatment had no significant effect on cell survival in the
RGC layer. Even with an injection of 0.9% saline there was significant cell loss in
the RGC layer 1 month after surgery.

Effects of PNU-120596, an al nAChR modulator: in vitro and in vivo
Binding studies have demonstrated that PNU-282987 acts as an agonist on
a7nAChRs and that PNU-120596 acts to enhance a7nAChR receptor activity
(Bodnar et al.,2005). To examine any modulatory effect of PNU-120596 in rat
cultured retinal tissue, intitial in vitro experiments were performed to examine if
PNU-120596 provided neuroprotection against glutamate-induced excitotoxicity. As
shown in fig. 18, when cells were cultured with different concentrations of the a7
ACh modulator, PNU-120596, before the glutamate insult, lOnM of the modulator
provided neuroprotection against RGC loss.
modulator

Higher concentrations of the a7

(lOOnM, luM lOuM) had little effect on cell survival or led to a

significant decrease of cells compared to control conditions, likely due to toxic
effects caused by relativly high concentrations of the agent (Fig. 18).
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Figure 17: Effects of PNU-282987 on cell loss in the glaucoma model
Bar graphs summarize the results associated with using PNU-282987 (agonist) in
the glaucoma model. To generate this figure, the number of cells in the RGC layer
was counted and normalized to their corresponding internal control (left eye). Each
bar represents the mean % of cells in the RGC layer compared to the internal
control.* represents significance from control. Averages were obtained from
between 3-9 experiments. Error bars represent SEM.
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Figure 18: Dose dependent effects of PNU-120596 on cultured RGCs
Bar graphs summarize the effect of the PNU modulator, on cultured large RGCs.
The RGCs were cultured with various concentrations of the PNU modulator and 500
uM glutamate. At lOnM, the a7 nAChR modulator by itself provided
neuroprotection against glutamate-induced cell loss. * indicates significance from
control. # indicates significance from glutamate conditions. Bar averages were
obtained from cell counts obtained from between 3-9 rats.

These results suggests that the a7 modulator, by itself, had neuroprotective
effects against glutamate-induced excitotoxicity at one concentration. However a
modulator should only modulate the receptor if ACh or ACh agonists are bound to the
receptors. Since the RGCs were not isolated during the culturing process, it was
hypothesized that there may be starburst amacrine cells present in culture that would
release ACh in the in vitro model. This would allow the PNU modulator to act on the
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receptor to modulate levels of neuroprotection. To test this hypothesis, the cultures of
retinal cells were stained with a antibody against choline acetyltransferase (ChaT) to
verify the existence of cholinergic starburst amacrine cells in the rat RGC culture
(Fig. 19). When stained with the anti ChaT antibody, cholinergic cells were visible
throughout the retinal culture in relatively low numbers (Fig. 19). When cells were
stained without the primary antibody in control studies, no cells were visible (data not
shown). This result supports the hypothesis that cholinergic amacrine cells are
present in the primary culture of retinal cells, and is a plausible reason that the PNU
a7 modulator could provide neuroprotection in culture.

Figure 19: Amacrine cell staining using ChaT
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Dissociated rat retina was cultured for 3 days, fixed and labeled with a primary
antibody against Choline Acetyltransferase and secondarily labeled with Alexa Fluor
388 for visualization. Arrow represents amacrine cells stained with ChaT.
Combined effects of both PNU compounds
In culture, the PNU a7 agonist and modulator had considerable
neuroprotective effects against glutamate-induced excitotoxicity when applied
separately.

I was interested in seeing what the effects of the a7 agonist and

modulator would be if they were applied together before glutamate insult.
Interestingly, when 100 nM PNU-282987 and lOnM PNU-120596 were combined
together before applying the glutamate insult, cell survival was significantly higher
than control levels at 154.38% (SE ±2.74) after 3 days in culture (Fig. 20) Thus, the
combination of these agents appears to not only provided neuroprotection against
glutamate-induced excitotoxicity, but also prevented loss of RGCs that normally
occur during the cell culture process. This is likely due to the combination of both
PNU compounds protecting against normal damage occuring during the 3 days the
cells are cultured. These results are consistent with our hypothesis that introduction
of a7 nicotinic agonists or modulators can significantly reduce the loss of cells in the
RGC layer that is normally associated with glaucoma.
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Figure 20: Summary data of RGCs in vitro
These bar graphs summarize the results of the effects of the PNU compounds in cell
culture. To generate this figure, the # of RGCs cultured under the various conditions
were counted and normalized o the corresponding control conditions for each
experiment. * indicates significance from glutamate conditions. # indicates
significance from control conditions. Bar averages were obtained from counts
obtained from between 3-9 rats. Combo indicates that both PU-282987 and PNU120596 were applied simultaneously.

Effects of PNU agents in vivo
Figure 21 represents sample images obtained from the rat's RGC layer 1
month after surgery to induce glaucoma in the rat's right eye. The left columns
represent control untreated images obtained from the same area of the peripheral
retina as shown in the corresponding right column. The images in each row were
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obtained from the same animal. Panel A was obtained from peripheral retina under
control untreated conditions. To obtain the image in fig. 2IB, hypertonic saline was
injected into the episcleral vein to induce cell loss in the RGC layer and
fragmentation of distinct axon tracts. Panel C and D were obtained from another rat,
where the right eye was injected with 5ul of lOOuM PNU a7 agonist into the
vitreous 1 hour before surgery to induce glaucoma. As shown in these 2 images, the
a7nAChR agonist prevented the cell loss normally associated with hypertonic saline
injection. This is also the effect seen when the a7nACh modulator PNU-120596
was injected before surgery. There is no significant difference between the number
of cells in the treated eye compared to the internal control, obtained from the same
regions of the retina from the same animal and there was no obvious change in the
thickness or direction of the axon tracts. Figure 2IF depicts an example image
obtained from the right eye of a rat injected with a7 ACh modulator, PNU-120596,
before surgery and the figure E represents an internal image from the left eye control
of the same rat. When both PNU agonists were injected prior to the glaucoma
surgery, there was no significant difference between the number of cells in the RGC
layer comparing the left and right eye (figs. G and H). The results observed from in
vitro studies that demonstrated a higher number of cells in the culture treated with
both PNU compounds compared to control were not evident in the in vivo model.
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These results support the hypothesis that the introduction of a7 nicotinic agonists or
modulators can significantly reduce the loss of cells in RGC layer associated with
our glaucoma model.
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Figure 21: Effects of both PNU compounds in vivo
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Each panel represents an image obtained from the peripheral of the rat retina under
the following conditions. (A) control untreated eye, (B) glaucoma-induced eye from
the same animal and from the same region of the retina as shown in A. (D) an image
sample from a rat eye injected with the PNU a7 agonist before surgery to induce
glaucoma, (F) an image obtained 1 month after the a7 modulator was injected prior
to surgery, (H) is an image obtained in an eye co-injected with the PNU modulator
and agonist together prior to surgery to induce glaucoma. The left column
represents the internal control from the same animals that the experimental images
were obtained from (right colum). All iamges were obtained 1 month following
surgery to the right eye. Scale bar represents 50um.

The bar graphs represented in Fig. 23 summarize the results of the PNU
agonist and modulator experiments in the in vivo rat glaucoma model. Injection of
hypertonic saline to induce loss of cells in the RGC layer resulted in an overall
average loss of cells in the RGC layer by 23.86%) (SE±6.68).

Injecting the the a7

ACh agonist, PNU-282987 or the a7 ACh modulator, PNU-120596 before surgery
to induce cell loss, eliminated the glaucoma effect and had a significant
neuroprotective effect in increasing cell survival to 99.36% (SE±3.46) and 102.00%)
(SE±6.06) respectively. When a combination of PNU agonist and modulator was
injected prior to the glaucoma surgery, the cell survival was comparable to the
control eye (Fig. 22). These results support the hypothesis that introduction of a7
nicotinic agonists and/or modulators can significantly reduce the loss of cells in
RGC layer associated with our glaucoma model.
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Figure 22: In vivo studies using PNU compounds
Cells in the RGC layer were counted and normalized to their internal control (left
eye) 1 month after various treatments. Agonist indicated application of PNU282987, modulator indicated application of PNU-120596 and combo indicates coapplication of both PNU compounds before surgery to induce glaucoma. * indicates
significance from control. Error bars represent SEM.
Labeling RGCs in vivo
Although careful consideration was given to count cells from specific
preipheral regions in the RGC layer in vivo, cresyl violet stains all cell bodies that
contain nissl substance, so it is uncertain if the cell counts fully represent the RGC
population. Figure 23 represents images obtained from the peripheral retina after
RGCs were stained with the Thy 1.1 antibody. Figure 23A is an image obtained
from a untreated control retina. An average of 11.22% (SE+/-2.21) of cells in images
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obtained from the periphery in the RGC layer did not label with the primary
antibody (n=6). This suggests that the majority of cells in the peripheral rat retina in
the RGC layer are RGCs.
Fig. 23B was obtained from the same animal's right eye 1 month after
glaucoma surgery. There was an average loss of 28.12%) (±3.2, n=6) of RGCs
compared to the internal control. Though we have not identified the 11% of cells in
the RGC layer that did not stain with antibody against Thy 1.1, previous studies
have demonstrated that there is a population of displaced amacrine cells in the RGC
layer in rats (Perry et al. 1980). However, the displaced amacrine cells are not prone
to cell death induced by glaucoma (Kielczewski, 2005), therefore we can speculate
that the loss of cells in the RGC layer from the surgical procedure to induce
glaucoma, are primarily RGCs.
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Figure 23: RGCs labeled with Thy 1.1
A) an image obtained from the untreated left eye of a rat. Arrows indicate axon
tracts. B) an image obtained from the right eye from the same animal 1 month after
surgery to induce glaucoma.
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DISCUSSION

Excitoxicity

This study was designed to test the neuroprotective properties of a specific
nAChR agonist and modulator against excitotoxicity in rat cell culture and against
glaucoma-like conditions using an in vivo rat model. The excitotoxic effect of
glutamate on cultured RGCs was previously examined using isolated pig RGCs
(Luo et al., 2001; Wehrwein et al., 2005).

We found that glutamate-induced

excitotoxicity was also present in rat. In vitro studies demonstrated that 500uM
glutamate caused an average of -45% RGC loss after 3 days in dissociated rat
retinal cell culture. When excitotoxicity was induced using KA, RGC survival
decreased by -34%. This cell loss was significant compared to control conditions,
however it did not equal the cell loss with glutamate. The excitotoxic effect of KA
was eliminated when CNQX, an antagonist specific to the KA receptor was applied.
NMDA also induced excitotoxicity and caused an average loss of RGC of 23%
compared to control. Again NMDA's effect represented a significant decrease of
RGCs but it did not match the degree of loss associated with glutamate. The effect
of NMDA was eliminated when MK-801, an antagonist specific to the NMDA GluR,
was applied before NMDA. Thus it appeared that both KA and NMDA receptors
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play a role in excitotoxicity in rat RGCs. To confirm this, when cells were cultured
in a combination of NMDA and KA, cell survival decreased by an average of 43%
which mimicked the excitotoxic effect of glutamate. If KA and NMDA were
applied after the application of the antagonists, MK-801 and CNQX, their
excitotoxic effect was eliminated.

This suggests that glutamate-induced

excitotoxicity was mediated though both NMDA and non-NMDA receptors which is
consistent with data that indicates both types of GluRs can be found in the ganglion
cell population (Muller et al., 1992, Hamassaki-Britto et al., 1993). These results are
also consistent with pig studies done in this and other labs (Luo el al., 2001;
Wehrwein et al., 2004).
Excitotoxicity and apoptosis has been associated with glaucoma in the eye
and other neurodegenerative diseases in the brain. For instance, in Alzheimer's
diseases, the loss of cognitive function is caused by apoptosis of neuronal cells
(Niikura et al., 2006).

Similar to results obtained in these glaucoma studies,

neuroprotection against Alzheimer's disease has been linked to activity of
a7nAChRs. Epidemiological studies showed that nicotine decreased the risk for AD
(Fratiglioni and Wang, 2000). This negative association is in agreement with
postmortem studies showing significant reduction of amyloid plaque deposits in
former smokers with AD (Hellstrom-Lindahl el al., 2004a). Nicotine treatment
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appears to interfere with the formation of the amyloid plaques in vitro and in vivo
(Ono et al., 2002; Utsuki et al., 2002; Hellstrom-Lindahl el al., 2004a) and to reduce
the accumulation of insoluble P-amyloid peptides (Nordberg et al., 2002) through a
mechanism mediated by a7nAChRs as demonstrated in inhibition studies using
neuroblastoma cells.

In these inhibition studies, the a7nAChR antagonist,

mecamylamine, was used to block nicotine's effect (Hellstrom-Lindahl el al., 2004b).

Neuroprotection

In this study, we examined the neuroprotective properties of 2 compounds
specific to the a7nAChR. PNU-282987 is an agonist specific to the a7nAChR, and
PNU-120596 has previously been shown to modulate this a7 receptor. Many
laboratories have examined potential neuroprotective agents against glutamate
excitotoxicity, by directly affecting the glutamate receptor with antagonists or by
using other pharmacological agents that affect other specific receptors (Niikura et al.,
2006). Other studies have looked at neurotrophic factors that affect the physiology
to provide neuroprotection (Jiang, 2007).

In this study I propose that

neuroprotection can be triggered through ACh receptors found on RGCs.
In excitotoxic models, RGC death is thought to be caused by a large influx of
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Ca through glutamate receptor channels. However, we have shown that by adding
ACh before a large glutamate insult, we are able to protect the RGCs. This suggests
that ACh perhaps released from cholinergic starburst amacrine cells, may have a
physiological neuroprotective effect under normal conditions. If so, this would
represent a new role previously not understood associated with starburst amacrine
cells.

However when the retina is glaucomatous, these naturally occurring

neuroprotective defense mechanisms could either be overwhelmed or ACh release
from the starburst amacrine cells could be diminished. Since previous studies have
shown that cholinergic amacrine cells are not lost in glaucoma-like conditions, other
factors are likely responsible for the loss of neuroprotection (Kielczewski et al.,
2005). For example, ACh release from the cells could be compromised. A decrease
in ACh could be due to other extrinsic effects that compromise the starburst
amacrine cell population directly, or indirectly affect the release of ACh from the
amacrine cells. There is also the possibility that glutamate excitotoxicity or some
aspect associated with the glaucoma condition could be affecting the ACh receptors
at the RGC level by modifying the binding site or causing internalization of
receptors (Shen et al., 2010).
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Pig vs. rat

The in vitro studies using rat retina were done to determine if the excitotoxic
and neuroprotective studies done in previous pig studies could be mimicked using
rat tissue. In the rat study, the retina was dissociated but RGCs were not isolated.
This procedure was done in the rat to increase cell density. Rat eyes are significantly
smaller than pig eyes and many more rat eyes would be required in each experiment
to maintain cell densities sufficient to sustain healthy culture systems. However in
both methods, Thy 1.1 was used to identify the glycoprotein found exclusively on
RGCs in the retina.
When comparing RGC death in pig and rat studies, 500uM of glutamate
caused similar reductions of large RGCs in 3 days (rat 45% vs pig 42%). In both
models the small RGCs were more resistant to damage than large RGCs. An
average of 32% of small RGCs were eliminated with glutamate in pig studies while
an average of 25% of small RGC were lost in rat studies. Surgery to induce
glaucoma-like resulted in cell loss by more than 25%. Since starburst amacrine cell
are not normally eliminated under glaucoma conditions (Kielczewski et al., 2005), it
is likely that a significant number of cells that are lost in the RGC layer after
hypertonic injections are RGCs.
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In respect to neuroprotection from ACh and nicotine, both compounds
protected against excitotoxicity in a dose dependent manner.

For both the rat and

pig, if the cells were pretreated with ACh, there was significant neuroprotection
against 500uM glutamate. ACh applied at lOuM eliminated RGC death due to
excitotoxicity completely. Nicotine had similar neuroprotective properties in both
pig and rat studies.

For the pig studies, maximum neuroprotection against

excitotoxicity was observed when lOuM nicotine was used. From in vitro results
using the rat, lOOuM concentrations had maximal protection before cell survival
began to decrease due to non-specific effects. Therefore nicotine and ACh provided
neuroprotection against excitotoxicity in rat and pig studies, but to different degree
and at different concentrations

Counting cells in the RGC layer

In original in vivo studies, cell counts were obtained from a flat mounted
retina and cell bodies were stained with cresyl violet to visualize the cell bodies in
the RGC layer. The cresyl violet stains cell bodies that contain nissl substance
which is composed of rough endoplasmic reticulum. In the RGC layer, besides
RGCs, there are Mueller cells, displaced amacrine cells and microglia. In some
areas of the retina, the contribution of these other cells can be significant (Bernstein
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and Guo, 2011). To address this issue, Thy 1.1, a glycoprotein found exclusively on
RGCs in the retina, was used to verify that the loss of cells in the RGC layer that
results from inducing glaucoma-like conditions are from the RGC population. The
results of the specific staining of RGCs demonstrated that only an average of
11.22%) (±2.21) of cells in the peripheral RGC layer were not RGCs, as they did not
label with an antibody against Thy 1.1.

Implications and future studies

The main risk factor for glaucoma is an increase in IOP and all current
therapies are designed to decrease IOP. However, other characteristics of the disease
involve excitotoxicity and loss of RGCs and are more proximal to loss of function.
In this study, I propose that pretreatment of the retina with an a7nAChR agonist
might be used to prevent the excitotoxicity and loss of RGCs normally associated
with glaucoma-like conditions. This would represent a different strategy for dealing
with glaucoma and would be most beneficial for patients with a history of glaucoma
in their family or could be beneficial to aged patients by preventing glaucoma from
ever developing. Since the PNU compounds directly affect RGCs, this treatment
could be used in any type of patient regardless of IOP. It is however best suited for
patients as a preventative measure for people at high risk for glaucoma based on age,
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genetics or race, since all our studies demonstrated that cells have to be
preconditioned with a7 agonist. In fact, no neuroprotection occurs if the agents are
given at the same time or after the glutamate insult (Wehrwein et al., 2004).
Though nicotine and other ACh agonists can produce similar neuroprotective
effects, there are benefits of using specific agonists and modulator against the a7
nicotinic receptor on RGCs. Both PNU compounds used in this study are specific to
the a7 nAChR. This specificity can be a great benefit physiologically. If used as an
anti-glaucoma drug, the more specific an agent is to a certain receptor, the less side
effects it will exert in the body.

Broad general agonists can bind to multiple

subtypes of receptors and can cause unwanted side effects. To avoid unwanted side
effects, the method of drug delivery is also important.

In this study, the PNU

compounds were directly injected inside the eye via intravitreal injections. However,
other non-invasive drug delivery methods to the eye may be beneficial. Delivery to
the retina via topical eye drops has been shown to get PNU-282987 to the rabbit
retina. When applied as eye drops, PNU-282987 reaches concentrations in the retina
comparable to other glaucoma medications and remains in the retina at least 8 hours
after application (Linn D. et al 2011). This could provide extended neuroprotection
within the eye and is enough time to trigger cell survival pathways (Asomugha et al.
2010). More invasive methods such as systemic delivery though IP injections or
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through transdermal patches can also produce prolonged effects and have been
shown to provide neuroprotection in the rat glaucoma model (Linn C. et al., 2011),
but these delivery methods will produce more side effects, as there are a7nAChR
throughout the body and CNS.
One of the objectives of the present study was to compare previous
excitotoxicity studies done with the pig with the current animal model using the rat.
I also wanted to explore the effect of an a7 specific agonist and modulator against
glutamate excitotoxicity and to test these agents against glaucoma-like conditions in
an in vivo rat model. The results of this study suggest that neuroprotection against
glutamate-induced excitotoxicity is not species specific as both pig and rat RGC can
be protected against glutamate -induced excitotoxicity with pretreatment of ACh,
nicotine and a7 specific PNU compounds.
The mechanism of cellular loss due to glutamate in rat RGCs is still
unknown.

However, previous studies done in pig studies have linked

overstimulation of glutamate receptors to apoptosis (Asomugha et al., 2000). These
previous studies found that excessive glutamate triggered p38 MAP kinase to initiate
apoptotic cascade. This same mechanism could also occur in the rat, though further
studies would be needed to support this.
The neuroprotective properties of both the PNU-282987 and PNU 120596
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are promising but the mechanism responsible for neuroprotection in the in vivo
system is still unknown and still need to be studied. Based on previous studies in
pig, it can be postulated that glutamate and glutamate agonist, NMDA and KA, can
trigger apoptotic pathways while ACh and ACh agonists decrease these apoptotic
pathway and increase cell survival and proliferation through neuroprotective
intracellular pathways (Asomugha et al., 2010). Other studies have shown that
activation of PI3 kinase triggers a cell survival pathway in the retina. (Alvarez,
2009; Asomugha et al., 2010). Other compounds, such as brain-derived neurotrophic
factor, can also protect RGCs through the PI3 kinase pathway (Nakazawa et al.,
2002). Previous studies done in this lab have linked Ca2+ influx though nAChR
channels to neuroprotection in pig RGCs (Brandt et al., 2011), but similar studies
must be repeated in the rat using ACh and the PNU compounds to determine if
similar links prevail.
In glaucoma conditions, it is still unknown if excitotoxic conditions
overwhelm endogenous neuroprotective mechanisms through AChRs, or if
neuroprotective mechanisms are blocked or decreased.

Previous studies have

demonstrated that the number of amacrine cells is not affected in experimental
glaucoma models, and that most of the cell loss associated with glaucoma is from
RGCs (Kielczewski et al., 2005). This was supported in my results. When Thy 1.1
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was used as a specific label for RGCs in a flat mounted retina, approximately 90%
of observable cells in the RGC layer were labeled, indicated that the vast majority of
cells located in the RGC layer in the peripheral retina are RGCs. One month after
injection of hypertonic saline, there was a significant loss of these labeled RGCs.
If glaucoma conditions target only the RGCs specifically and there is no
decrease in number of amacrine cells, why doesn't endogenous ACh protect against
the injection of 2M hypertonic saline that induces glaucoma-like condition? There
may be other mechanisms that decrease neuroprotection. Though the amacrine cells
may be intact, the release of ACh from these starburst amacrine cells could be
compromised. There could also be a change in the acetylcholinesterase (AChE), an
enzyme that breaks down ACh. In fact, a study done using Galantamine, an AChE
inhibitor, has been shown to have neuroprotective effects in glaucoma models
(Almasieh et al., 2010). Future studies need to be conducted that analyze any
change in release of ACh from the amacrine cells. Alternatively, a change in the
number or affinity of receptors on the RGC may occur to compromise the
neuroprotective properties of ACh in our glaucoma model.
In this study, we reported that both large and small RGCs are affected by
excitotoxicity. In previous studies done in lab using pig, it was shown that the a7
receptors are primarily found on the large RGC type, however, it is unknown if this
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is the case for Long Evans rats. When analyzing PNU's effect on rat RGCs in
culture, PNU agonist provided complete neuroprotection on large RGCs. In small
RGCs,

PNU-282987

provided

partial

neuroprotection

against

glutamate

excitotoxicity. This suggests that a7 receptors are also present on small RGCs found
in the retina in rat.
Although, PNU compounds prevent loss of cell from the RGC layer after the
hypertonic injection, future studies must be done to address the function of these
protected cells. Even though the number of RGCs do not change in the presence of
PNU, it is important to verify that these cells function normally. To test this,
electrophysiological studies must be done on the RGCs to determine if there are any
changes in ion channel activity or to determine if there are any differences in
response to protection.
When both PNU compounds were applied in vitro, there was a significant
increase in the number of cells compared to control (Fig 20). What caused this
increase in cell numbers beyond control levels in the in vitro model is unknown but
a few speculations can be made. In the in vitro model, untreated control RGCs
began to decrease in numbers by 3 days due to the dissociation and culture
procedure (fig. 24). By day 7, approximately 50%) of cells originally plated survived
in control untreated conditions. PNU-282987 and PNU 120596 alone protected the
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cells against glutamate excitotoxicity, however when used together, they protected
RGCs from the excitotoxic effects of glutamate as well as from cell loss normally
associated with the dissociation process (fig. 24). This is a plausible explanation as it
is unlikely that there's an increase of RGCs in culture as adult neurons do not divide.
It is, however, possible that there's an increase of RGCs due to the combination of
PNU agonist and modulator, which acts together to lower the amount of normal cell
death that normally accompanies the culture procedure.

The increase in cell

numbers beyond untreated conditions was not observed in the in vivo model of
glaucoma.

150-1

o100-

#

#

*

O
O
S? 50-

J?

J

J"

&

^

&

J>

v*

Figure 24: Both PNU compounds increase RGC counts
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Each normalized data bar represents the percentage of cells that survived compared to
control untreated conditions at Day 0. The PNU combination represents the percent
survival of RGCs after three days in culture with lOOnM PNU-282987 and lOnM
PNU-120596 before 500uM glutamate. # represent significance from glutamate, and
* represents significance from control untreated conditions. Normalized data were
obtained from between 3-9 experiments. Error bars represent SE.

If using the PNU agonist and modulator together in culture can protect
against normal cell damage and cell death associated with the dissociation process,
these compounds could be included in standard culture media for RGCs to increase
cell viability for researchers interested in culturing RGCs. Use of these agents may
also have promising effects in an in vivo model, or in human clinical settings. Long
term exposure to both compounds could be used to prevent normal cell death that
occurs in disease states such as glaucoma, but also as a preventative measure for
populations at high risk for RGC related ocular diseases.
In conclusion these data suggest that introduction of a7 nicotinic agonists
and the PNU modulator can significantly reduce the loss of RGCs associated with
glaucoma and glutamate excitotoxicity. It also strengthens the potential of the a7
nicotinic receptor as a potential therapeutic target for neuroprotection.
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